Free Trial

Biogen (BIIB) Competitors

Biogen logo
$152.21 -1.84 (-1.19%)
Closing price 10/7/2025 04:00 PM Eastern
Extended Trading
$152.44 +0.23 (+0.15%)
As of 04:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BIIB vs. AMGN, GILD, IONS, MRNA, PRTA, SAVA, VRTX, BMY, LLY, and PFE

Should you be buying Biogen stock or one of its competitors? The main competitors of Biogen include Amgen (AMGN), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Moderna (MRNA), Prothena (PRTA), Cassava Sciences (SAVA), Vertex Pharmaceuticals (VRTX), Bristol Myers Squibb (BMY), Eli Lilly and Company (LLY), and Pfizer (PFE). These companies are all part of the "medical" sector.

Biogen vs. Its Competitors

Biogen (NASDAQ:BIIB) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Biogen has a beta of 0.13, suggesting that its share price is 87% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500.

In the previous week, Amgen had 43 more articles in the media than Biogen. MarketBeat recorded 61 mentions for Amgen and 18 mentions for Biogen. Amgen's average media sentiment score of 1.12 beat Biogen's score of 0.97 indicating that Amgen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
9 Very Positive mention(s)
0 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Amgen
43 Very Positive mention(s)
2 Positive mention(s)
13 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Positive

Amgen has a net margin of 18.96% compared to Biogen's net margin of 15.31%. Amgen's return on equity of 174.71% beat Biogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen15.31% 13.85% 8.32%
Amgen 18.96%174.71%13.12%

Biogen presently has a consensus target price of $180.04, indicating a potential upside of 18.28%. Amgen has a consensus target price of $309.42, indicating a potential upside of 4.70%. Given Biogen's stronger consensus rating and higher probable upside, equities research analysts plainly believe Biogen is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
1 Sell rating(s)
20 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.31
Amgen
1 Sell rating(s)
12 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.30

87.9% of Biogen shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 0.7% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Amgen has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.68B2.31$1.63B$10.4614.55
Amgen$33.42B4.76$4.09B$12.2324.17

Summary

Amgen beats Biogen on 12 of the 16 factors compared between the two stocks.

Get Biogen News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIIB vs. The Competition

MetricBiogenMED IndustryMedical SectorNASDAQ Exchange
Market Cap$22.59B$3.35B$6.11B$10.65B
Dividend YieldN/A2.29%5.70%4.74%
P/E Ratio14.5521.4185.8226.85
Price / Sales2.31466.25616.35135.13
Price / Cash6.6747.6737.7861.77
Price / Book1.3310.0613.236.70
Net Income$1.63B-$52.22M$3.30B$276.44M
7 Day Performance-1.30%4.25%3.91%2.48%
1 Month Performance7.68%12.50%8.38%8.79%
1 Year Performance-16.51%26.68%88.63%34.41%

Biogen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIIB
Biogen
4.5644 of 5 stars
$152.21
-1.2%
$180.04
+18.3%
-17.0%$22.59B$9.68B14.557,605Analyst Forecast
AMGN
Amgen
4.5536 of 5 stars
$274.42
+0.5%
$309.70
+12.9%
-6.9%$147.64B$33.42B22.4228,000Trending News
GILD
Gilead Sciences
4.8877 of 5 stars
$112.53
+0.4%
$117.17
+4.1%
+38.3%$139.62B$28.75B22.4217,600Positive News
IONS
Ionis Pharmaceuticals
3.409 of 5 stars
$63.75
-0.5%
$73.88
+15.9%
+82.1%$10.16B$705M-34.631,069Analyst Forecast
MRNA
Moderna
4.3228 of 5 stars
$25.35
+3.5%
$41.81
+65.0%
-53.4%$9.88B$3.24B-3.375,800
PRTA
Prothena
3.0686 of 5 stars
$9.54
+1.3%
$19.75
+107.1%
-38.7%$514.08M$135.16M-1.69130News Coverage
Analyst Forecast
Gap Up
SAVA
Cassava Sciences
3.031 of 5 stars
$2.93
-2.2%
$2.00
-31.6%
-86.5%$141.31MN/A-1.1530
VRTX
Vertex Pharmaceuticals
4.8571 of 5 stars
$397.92
+3.2%
$493.81
+24.1%
-8.5%$101.81B$11.02B28.386,100Positive News
BMY
Bristol Myers Squibb
4.9828 of 5 stars
$44.21
+0.2%
$56.38
+27.5%
-16.5%$89.97B$48.30B17.8234,100Positive News
LLY
Eli Lilly and Company
4.9943 of 5 stars
$725.81
+0.2%
$939.61
+29.5%
-6.0%$687.01B$45.04B47.4447,000Trending News
PFE
Pfizer
4.9191 of 5 stars
$23.83
+0.3%
$28.12
+18.0%
-10.0%$135.46B$63.63B12.6781,000Trending News

Related Companies and Tools


This page (NASDAQ:BIIB) was last updated on 10/8/2025 by MarketBeat.com Staff
From Our Partners